Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Merck
McKesson
McKinsey
Moodys

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

LO LOESTRIN FE Drug Profile

See Plans and Pricing

« Back to Dashboard

When do Lo Loestrin Fe patents expire, and what generic alternatives are available?

Lo Loestrin Fe is a drug marketed by Apil and is included in one NDA. There is one patent protecting this drug.

This drug has nine patent family members in seven countries.

The generic ingredient in LO LOESTRIN FE is ethinyl estradiol; norethindrone acetate. There are twenty-six drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone acetate profile page.

Drug patent expirations by year for LO LOESTRIN FE
Drug Prices for LO LOESTRIN FE

See drug prices for LO LOESTRIN FE

Drug Sales Revenue Trends for LO LOESTRIN FE

See drug sales revenues for LO LOESTRIN FE

Recent Clinical Trials for LO LOESTRIN FE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bristol-Myers SquibbPhase 1
Purdue Pharma LPPhase 1
Eisai Inc.Phase 1

See all LO LOESTRIN FE clinical trials

Recent Litigation for LO LOESTRIN FE

Identify potential future generic entrants

District Court Litigation
Case NameDate
Teva Women's Health, Inc. v. Famy Care Ltd.2014-12-05
Warner Chilcott Company, LLC v. Amneal Pharmaceuticals, LLC2014-01-30
Warner Chilcott Company, LLC v. Lupin Ltd.2014-01-27

See all LO LOESTRIN FE litigation

PTAB Litigation
PetitionerDate
Mylan Pharmaceuticals Inc.2015-02-03

See all LO LOESTRIN FE litigation

Synonyms for LO LOESTRIN FE
19-Nor-17-alpha-pregn-4-en-20-yn-3-one, 17-hydroxy-, acetate mixed with 19-nor-17-alpha-pregna-1,3,5-(10)-trien-20-yne-3,17-diol
8015-12-1
8067-81-0
AC1L1Y7Y
Anovlar 21
Aurovela 1.5/30
Controvlar
Cumorit
Econ 30
ESTROSTEP 21
Etalontin
Ethinyl estradiol mixture with norethindrone acetate
Ethinyl oestradiol mixed with norethisterone acetate
Ethinylestradiol and norethindrone acetate
Gyn-Anovlar
Gynonlar
Gynonlar 21
Hailey Fe 1/20
Junel 1.5/30
Junel 1/20
Lo Loestrin
LOESTRIN 21 1.5/30
LOESTRIN 21 1/20
LOESTRIN FE 1/20
Microgestin
Microgestin 1.5/30
Microgestin 1/20
Minastrin 24 Fe
Neorlest
Norethindrone acetate and ethinyl estradiol
Norethindrone acetate and ethinylestradiol
Norethisterone acetate mixed with ethinyl oestradiol
NORLESTRIN 21 1/50
NORLESTRIN 21 2.5/50
NORLESTRIN 28 1/50
Primodos
SCHEMBL2523461
Sinovula
Taytulla
Trentovlane
Tri-legest 21
Paragraph IV (Patent) Challenges for LO LOESTRIN FE
Tradename Dosage Ingredient NDA Submissiondate
LO LOESTRIN FE TABLET;ORAL ethinyl estradiol; norethindrone acetate 022501 2011-04-29

US Patents and Regulatory Information for LO LOESTRIN FE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Apil LO LOESTRIN FE ethinyl estradiol; norethindrone acetate TABLET;ORAL 022501-001 Oct 21, 2010 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for LO LOESTRIN FE

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1453521 39/2015 Austria   Start Trial PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
1453521 93156 Luxembourg   Start Trial PRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
0771217 CA 2006 00038 Denmark   Start Trial PRODUCT NAME: ETHINYLESTRADIOL (SOM BETA-CYCLODEXTRIN-CLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 38687 20060627; FIRST REG. NO/DATE: EU RVG 31781 20050804
1453521 CA 2016 00016 Denmark   Start Trial PRODUCT NAME: LEVONORGESTREL OG ETHINYLOESTRADIOL; NAT. REG. NO/DATE: 56336 20151105; FIRST REG. NO/DATE: SK 17/0017/15-S 20150211
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKesson
Moodys
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.